NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
78.80 -1.00 (-1.25%) GOLD FUTURES
2,425.20 -13.30 (-0.55%) DOW
39,822.04 +15.27 (+0.04%) Bitcoin GBP
54,865.32 +1,193.33 (+2.22%)
Regulus Therapeutics Inc. (RGLS)
| Previous close | 2.0100 |
| Open | 1.9800 |
| Bid | 1.8700 x 100 |
| Ask | 1.9300 x 500 |
| Day's range | 1.8700 - 2.0300 |
| 52-week range | 1.0800 - 3.7900 |
| Volume | |
| Avg. volume | 3,234,961 |
| Market cap | 124.058M |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5800 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.25 |
PR NewswireRegulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer effective May 16, 2024. Dr. Garg previously served as the Company's Senior Vice President, Clinical Development and Regulatory.
- PR Newswire
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
- PR Newswire
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three
